TA
DGX icon

TruWealth Advisors’s Quest Diagnostics DGX Stock Holding History

TruWealth Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,050
Closed -$406K – 162
2024
Q1 		$406K Buy
3,050
+104
+4% +$13.5K 0.03% 111
2023
Q4 		$406K Buy
2,946
+277
+10% +$36.4K 0.03% 102
2023
Q3 		$325K Buy
2,669
+535
+25% +$71.3K 0.03% 107
2023
Q2 		$300K Sell
2,134
-50
-2% -$6.89K 0.03% 114
2023
Q1 		$309K Sell
2,184
-24
-1% -$3.43K 0.03% 112
2022
Q4 		$345K Buy
+2,208
New +$317K 0.03% 102

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

TruWealth Advisors's DGX Position: Q2 2024 in Review

TruWealth Advisors sold out of Quest Diagnostics (DGX) in Q2 2024, closing a stake of 3,050 shares — an estimated $406K sold.

TruWealth Advisors first reported a position in DGX in Q4 2022 and held it in 6 quarters. The position peaked at $406K in Q4 2023. 838 funds tracked by Wall St. Rank hold DGX as of Q2 2024.

  • TruWealth Advisors reported no remaining Quest Diagnostics position as of Q2 2024 after selling out during the quarter.
  • TruWealth Advisors sold 3,050 Quest Diagnostics shares in Q2 2024, an estimated $406K.
  • TruWealth Advisors first reported a position in Quest Diagnostics in Q4 2022 and held it in 6 quarters.
  • TruWealth Advisors's Quest Diagnostics position peaked at $406K in Q4 2023.
  • 838 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2024.

Based on TruWealth Advisors's 13F filing for Q2 2024, filed 16 Jul 2024.